Italfarmaco licenses JCR’s Hunter syndrome therapy JR-141 for US, Europe, Latin America commercialization

• JCR Pharmaceuticals signed an exclusive license deal with Italfarmaco to develop JR-141 for Hunter syndrome in the US, Europe, Latin America.
• Italfarmaco receives exclusive commercialization rights in the licensed territories, contingent on regulatory approvals.
• JCR keeps manufacturing responsibility; deal includes upfront, milestone, royalty payments, plus supply revenue.
• JR-141 is a blood-brain barrier–penetrating enzyme replacement therapy; JCR is running a global Phase III trial.
• Upfront payment was incorporated into JCR’s earnings forecast for the fiscal year ending March 31, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JCR Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610020230BIZWIRE_USPR_____20261001_BW541148) on October 02, 2026, and is solely responsible for the information contained therein.